Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review

Introduction: Attention deficit hyperactivity disorder (ADHD) is generally treated with pharmacologic and non-pharmacologic interventions. Methylphenidate is the most widely used drug and is available to most patients. Purpose: To identify, synthesize and evaluate the best available evidence on the...

Full description

Bibliographic Details
Main Authors: José Calleja, José Uribarri
Format: Article
Language:English
Published: Medwave Estudios Limitada 2012-09-01
Series:Medwave
Subjects:
Online Access:http://dx.doi.org/10.5867/medwave.2012.08.5472
id doaj-dda48daf705744aa8e58a2d6bc203ab2
record_format Article
spelling doaj-dda48daf705744aa8e58a2d6bc203ab22020-11-24T23:46:49ZengMedwave Estudios LimitadaMedwave0717-63842012-09-011208e5472Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic reviewJosé CallejaJosé UribarriIntroduction: Attention deficit hyperactivity disorder (ADHD) is generally treated with pharmacologic and non-pharmacologic interventions. Methylphenidate is the most widely used drug and is available to most patients. Purpose: To identify, synthesize and evaluate the best available evidence on the effectiveness and safety of methylphenidate (MPH) in ADHD in the 6-19 year-old population. Methods: A systematic review of intervention studies was conducted with time limit February, 2012, in English and Spanish. The following databases were consulted: PubMed/MEDLINE, LILACS, Cochrane, DARE and National Guideline Clearinghouse. The articles were independently evaluated by two investigators and were assessed for methodological quality. Results: Of the 377 studies found initially, 14 were included, including two systematic reviews, 7 primary articles on therapeutic interventions and 5 clinical guidelines. Most of the studies have shortcoming with regards to search strategies, critical analysis, small samples and low Jadad scale. Conclusions: MPH is superior to placebo for moderate to severe cases of ADHD in the of 6-19 year-old population. http://dx.doi.org/10.5867/medwave.2012.08.5472attention deficit disorder with hyperactivitymethylphenidatesystematic review
collection DOAJ
language English
format Article
sources DOAJ
author José Calleja
José Uribarri
spellingShingle José Calleja
José Uribarri
Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review
Medwave
attention deficit disorder with hyperactivity
methylphenidate
systematic review
author_facet José Calleja
José Uribarri
author_sort José Calleja
title Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review
title_short Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review
title_full Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review
title_fullStr Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review
title_full_unstemmed Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review
title_sort effectiveness and safety of methylphenidate for adhd in population between 6 and 19 years: a systematic review
publisher Medwave Estudios Limitada
series Medwave
issn 0717-6384
publishDate 2012-09-01
description Introduction: Attention deficit hyperactivity disorder (ADHD) is generally treated with pharmacologic and non-pharmacologic interventions. Methylphenidate is the most widely used drug and is available to most patients. Purpose: To identify, synthesize and evaluate the best available evidence on the effectiveness and safety of methylphenidate (MPH) in ADHD in the 6-19 year-old population. Methods: A systematic review of intervention studies was conducted with time limit February, 2012, in English and Spanish. The following databases were consulted: PubMed/MEDLINE, LILACS, Cochrane, DARE and National Guideline Clearinghouse. The articles were independently evaluated by two investigators and were assessed for methodological quality. Results: Of the 377 studies found initially, 14 were included, including two systematic reviews, 7 primary articles on therapeutic interventions and 5 clinical guidelines. Most of the studies have shortcoming with regards to search strategies, critical analysis, small samples and low Jadad scale. Conclusions: MPH is superior to placebo for moderate to severe cases of ADHD in the of 6-19 year-old population.
topic attention deficit disorder with hyperactivity
methylphenidate
systematic review
url http://dx.doi.org/10.5867/medwave.2012.08.5472
work_keys_str_mv AT josecalleja effectivenessandsafetyofmethylphenidateforadhdinpopulationbetween6and19yearsasystematicreview
AT joseuribarri effectivenessandsafetyofmethylphenidateforadhdinpopulationbetween6and19yearsasystematicreview
_version_ 1725492104565620736